Video
ARVO LIVE: Trefoil Therapeutics CEO gives update on TTHX1114 in patients with FECD
Author(s):
Ophthalmology Times® talked with David Eveleth, MD, CEO and Founder of Trefoil Therapeutics about TTHX1114 in patients with Fuchs endothelial corneal dystrophy (FECD) undergoing Descemet’s Stripping Only (DSO) in combination with cataract surgery at this year's ARVO meeting.
Ophthalmology Times® talked with David Eveleth, MD, CEO and Founder of Trefoil Therapeutics about TTHX1114 in patients with Fuchs endothelial corneal dystrophy (FECD) undergoing Descemet’s Stripping Only (DSO) in combination with cataract surgery at this year's ARVO meeting.
Video transcript
Editor’s note: Transcript lightly edited for clarity.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
